FundraiseAug 20, 2026, 09:49 UTC

Bewe Lab awarded CHF 250,000 convertible top-up

What's the deal? Bewe Lab, a University of Fribourg spin-off building a neuroscience-based digital intervention for unhealthy food cravings, has been awarded Biopôle's Pre-Clinical Top-Up. The award is a CHF 250,000 (roughly $312,533) convertible loan designed to help startups cover high clinical validation costs.

Why now? The Top-Up follows a CHF 2 million raise from investors including Arcanys Ventures, Capital Risque Fribourg, Kickfund, the Foundation for Innovation and Technology, and Swisspreneur. Bewe had also taken part in Biopôle's Investment Readiness Program and Start-Up Fund, which financed research, development, and infrastructure while the team refined its business plan.

What's the endgame? The money will accelerate clinical studies generating evidence for Bewe's digital therapy, used alongside anti-obesity medication. It is working with academics at Stanford University and the Centre Pluridisciplinaire Neuchâtelois de l'Obésité to evaluate how behavioural therapy can improve long-term outcomes and reduce weight regain after medication stops.

What's next? Over the coming year, Bewe will start enrolling patients in US and Swiss trials and launch an AI-powered Digital Twin platform delivering personalised cognitive interventions. Longer term, it aims to reach one million users and extend its platform beyond obesity to other addictive behaviours, including alcohol and nicotine, across Switzerland, Europe, the UK, and the US.

The signal: At CHF 250,000, this is a modest, milestone-driven cheque — it sits in roughly the bottom third of comparable rounds by size. But convertible top-ups like this are how European deep-tech health startups bridge the costly gap toward clinical proof, where the real value is unlocked.